Workflow
Prevnar family
icon
Search documents
Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings
ZACKS· 2025-08-05 14:32
Core Insights - Pfizer reported revenue of $14.65 billion for the quarter ended June 2025, reflecting a 10.3% increase year-over-year and a surprise of +6.35% over the Zacks Consensus Estimate of $13.78 billion [1] - The earnings per share (EPS) for the quarter was $0.78, which is an increase from $0.60 in the same quarter last year, resulting in an EPS surprise of +34.48% compared to the consensus estimate of $0.58 [1] Revenue Performance by Segment - Oncology revenue from Elrexfio was $50 million, exceeding the average estimate of $34.33 million [4] - Primary Care revenue from Comirnaty in the United States was $176 million, significantly higher than the average estimate of $62.19 million [4] - Primary Care revenue from the Prevnar family internationally was $523 million, slightly below the estimate of $536.11 million, representing a -0.8% change year-over-year [4] - Primary Care revenue from the Prevnar family in the United States was $860 million, surpassing the estimate of $826.39 million, with a year-over-year increase of +3.4% [4] - Oncology revenue from Ibrance worldwide was $1.05 billion, matching the average estimate, but showing a -7.2% year-over-year decline [4] - Specialty Care revenue from Xeljanz worldwide was $322 million, exceeding the estimate of $219.35 million, with a +6.3% year-over-year increase [4] - Specialty Care revenue from Inflectra worldwide was $139 million, surpassing the estimate of $101.04 million, reflecting a +43.3% change year-over-year [4] - Oncology revenue from Xtandi worldwide was $566 million, exceeding the estimate of $528.19 million, with a +14.3% year-over-year increase [4] - Oncology revenue from Inlyta worldwide was $243 million, above the estimate of $205.85 million, but showing a -3.6% year-over-year decline [4] - Total Specialty Care revenue was $4.38 billion, exceeding the estimate of $4.19 billion, with a +7.2% year-over-year increase [4] - Total Primary Care revenue was $5.54 billion, surpassing the estimate of $5.11 billion, reflecting an +11.9% change year-over-year [4] - Primary Care revenue from the Prevnar family worldwide was $1.38 billion, slightly above the estimate of $1.36 billion, with a +1.8% year-over-year increase [4] Stock Performance - Pfizer's shares have returned -6.8% over the past month, contrasting with the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]
Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics
ZACKS· 2025-07-31 14:16
Core Viewpoint - Analysts project that Pfizer will report quarterly earnings of $0.58 per share, reflecting a 3.3% decline year over year, with revenues expected to reach $13.78 billion, an increase of 3.7% from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.2% lower over the last 30 days, indicating a collective reevaluation by analysts [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Projections - Analysts forecast 'Revenues- Oncology- Ibrance- Worldwide' to reach $1.05 billion, indicating a year-over-year decline of 6.9% [5]. - 'Revenues- Specialty Care- Xeljanz- Worldwide' is estimated at $219.35 million, reflecting a 27.6% decrease from the prior-year quarter [5]. - 'Revenues- Oncology- Xtandi alliance revenues- Worldwide' are expected to be $528.19 million, showing a year-over-year increase of 6.7% [6]. - 'Revenues- Specialty Care- Inflectra- Worldwide' is projected to reach $101.04 million, indicating a 4.2% increase year over year [6]. Regional Revenue Estimates - 'Revenues- Oncology- Ibrance- United States' is expected to be $702.67 million, reflecting a 5.2% decline year over year [7]. - 'Revenues- Specialty Care- Xeljanz- Total International' is estimated at $103.19 million, indicating a 15.4% decrease from the prior-year quarter [7]. - 'Revenues- Oncology- Ibrance- Total International' is projected to be $349.94 million, reflecting a 10.3% decline from the prior-year quarter [8]. - 'Revenues- Specialty Care- Xeljanz- United States' is expected to reach $116.16 million, indicating a significant year-over-year decline of 35.8% [8]. - 'Revenues- Oncology- Inlyta- Total International' is estimated at $89.23 million, reflecting an 11.7% decline from the prior-year quarter [9]. - 'Revenues- Oncology- Inlyta- United States' is projected to be $116.62 million, indicating a 22.8% decline year over year [9]. Primary Care Revenue Estimates - 'Revenue- Primary Care- Prevnar family- United States' is expected to be $826.39 million, reflecting a slight year-over-year decline of 0.7% [10]. - 'Revenue- Primary Care- Prevnar family- Total International' is projected to reach $536.11 million, indicating a 1.7% increase from the prior-year quarter [10]. Stock Performance - Pfizer shares have decreased by 6% in the past month, contrasting with the Zacks S&P 500 composite's increase of 2.7%, and the stock is expected to closely follow overall market performance in the near term [10].
Curious about Pfizer (PFE) Q1 Performance? Explore Wall Street Estimates for Key Metrics
ZACKS· 2025-04-24 14:20
Core Viewpoint - Pfizer is expected to report quarterly earnings of $0.64 per share, reflecting a 22% decline year-over-year, with revenues projected at $13.88 billion, a decrease of 6.7% compared to the previous year [1]. Earnings Estimates - Analysts have not revised the consensus EPS estimate for the quarter in the past 30 days, indicating a stable outlook among analysts [1]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock [2]. Revenue Projections - Analysts estimate 'Revenues- Oncology- Ibrance- Worldwide' at $898.97 million, down 14.7% from the prior year [4]. - 'Revenue- Specialty Care- Cibinqo' is projected to reach $71.20 million, an increase of 69.5% year-over-year [4]. - 'Revenues- Specialty Care- Xeljanz- Worldwide' is expected to be $141.92 million, down 26.9% from the previous year [5]. - 'Revenues- Oncology- Inlyta- Worldwide' is estimated at $207.30 million, indicating a 12.5% decline year-over-year [5]. Regional Revenue Insights - 'Revenues- Oncology- Ibrance- United States' is projected at $565.50 million, down 16.7% from the year-ago quarter [6]. - 'Revenues- Specialty Care- Xeljanz- Total International' is expected to be $101.82 million, reflecting a 15.2% decrease [6]. - 'Revenues- Oncology- Ibrance- Total International' is estimated at $333.47 million, down 11.1% year-over-year [7]. - 'Revenues- Specialty Care- Xeljanz- United States' is projected to be $40.10 million, indicating a significant decline of 45.8% [7]. Additional Revenue Metrics - 'Revenues- Oncology- Inlyta- Total International' is expected to reach $91.42 million, down 4.8% year-over-year [8]. - 'Revenues- Oncology- Inlyta- United States' is projected at $115.88 million, reflecting a 17.8% decline [8]. - 'Revenue- Primary Care- Prevnar family- United States' is estimated at $1.14 billion, a slight decrease of 0.4% from the prior year [9]. - 'Revenue- Primary Care- Prevnar family- Total International' is projected to be $550.39 million, indicating a year-over-year increase of 1.6% [9]. Stock Performance - Over the past month, Pfizer shares have returned -11.2%, compared to the Zacks S&P 500 composite's -5.1% [9]. - Pfizer currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [10].